Table 1.

The demographics, biodata, staging presentation, PSA, and Gleason grade group of patients with prostate cancer in sub-Saharan nations.

Study	No. of patients	Mean age in years	Age range in years	Staging presentation	PSA range	Mean PSA	Highest Gleason grade group
Diallo et al. (Senegal) [8]	156	75.3	52–100	Advanced/metastatic	1,300–2,104	1991.5	Group 4 (36%)
Botcho et al. (Togo) [9]	132	71 ± 12.6	45–99	Advanced/metastatic	5–9,998	1373.3 ± 1078	Groups 3–5 (46%)
Kirakoya et al. (Burkina) [10]	82	68.9 ± 9.5	49–95	98.6% (T3/T4) 40.2% metastasis	13–9,224	746	Group 1 (59.7%)
Ndoye et al. (Senegal) [11]	102	71 ± 9	51–96	Advanced/metastatic	5.88–21,660	1447.6 ± 812	Groups 2–5
Tengue et al. (Togo) [12]	232	68.5 ± 9.6		82.9% (T3/T4) 75.9% metastasis		123.5	Groups 2-3 (34.5%)
Ekwere and Egbe (Nigeria) [13]	145	66.6 ± 9.8	35–88	81.4% (T3/T4)
Kaboré et al. (Burkina) [14]	168	68.59 ± 9.41	30 to 95	86% (T3/T4)	1–7,421	483.3 + 145.4	Group 1 (60.1%)
Wasike and Magoha (Kenya) [15]	65	67	50–100	87.5% (T3/T4)			Group 4 (39.3%)
Kaboré et al. (Burkina) [16]	166	71.5	52–86	73.6% (T3/T4)	8.4–17,850	537	Groups 2-3 (54.7%)
Gueye et al. (Senegal) [17]	121	69	52–88	41.33% (T3/T4) 5.8% metastasis	6–578.9	72.2
Ikuerowo et al. (Nigeria) [18]	43	60.8		40% (T3/T4) 35% metastasis	0–438.3	2.5	Groups 2–5 (74.4%)
Badmus et al. (Nigeria) [19]	189	68	40–100	94.2% (T3/T4) 91% metastasis		106 ± 187
Folasire et al. (Nigeria) [20]	82	67 ± 1.8	47–87	Advanced/metastatic			Groups 4-5 (38%)
Yeboah et al. (Ghana) [21]	699	70 ± 0.04	41–94	25% (T3/T4) 13% metastasis	2.5–9,900	52.5	Groups 2–5 (67.7%)
Konan et al. (Ivory coast) [22]	362	67.4	44–97	68.2% metastasis	0–6000	315.0	Groups 2-3 (48.6%)
Sow et al. (Senegal) [23]	102	71.1 ± 8.6	54–88	Metastatic	PSA nadir	1,167.7	Group 3